News
APTO
--
0.00%
--
Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress
Benzinga · 2d ago
VXRT, NOVN, HTBX and CRIS among midday movers
Gainers: Novan (NOVN) +74%.Urban One (UONE) +39%.Iconix Brand (ICON) +28%.Aptinyx (APTX) +24%.Carver Bancorp (CARV) +22%.Vaxart (VXRT) +21%.Xinyuan Real Estate (XIN) +20%Broadway Financial (BYFC) +18%.Amesite (AMST) +18%.Siebert Financial (SIEB) +16%.Loser...
Seekingalpha · 2d ago
Aptose Biosciences Says Luxeptinib Treatment Shows Clinical Activity in Phase 1 A/B Trials for Acute Myeloid Leukemia, B Cell Malignancies
MT Newswires · 2d ago
Novan, Vaxart leads healthcare gainers; Orphazyme, Curis among major losers
Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%, Heat Biologics (HTBX) -23%.
Seekingalpha · 2d ago
Aptose tumbles on updated early-stage data luxeptinib in blood cancers
coffeekai/iStock via Getty Images Aptose Biosciences (APTO) has lost ~24.5% in early hours after the company announced updates on its clinical program for luxeptinib currently undergoing two Phase 1 a/b trials in blood cancers.
Seekingalpha · 2d ago
Vertex Pharmaceuticals, Orange, CureVac among premarket losers' pack
Orphazyme (ORPH) -49% Orphazyme stock losing half its value premarket, after rocketing fourfold the day beforeCVR Energy (CVI) -18%.Curis CRIS -13% on updated data for CA-4948 in blood cancers.Galecto (GLTO) -16%.Aptose Biosciences (APTO)
Seekingalpha · 2d ago
Aptose Presents Highlights from EHA During Corporate Update Event
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a corporate update event bein...
GlobeNewswire · 2d ago
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week, headlining the biotech news flow of the week.
Benzinga · 6d ago
Aptose to Hold Corporate Update Friday, June 11th
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS
GlobeNewswire · 05/27 11:30
Is the Options Market Predicting a Spike in Aptose (APTO) Stock?
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Zacks · 05/17 12:38
Aptose to Present at Upcoming Investor Conferences
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor ...
GlobeNewswire · 05/12 11:30
Caspase 3 Market Analysis (2021 - 2028)| By Key Players, Product Type, Application and Region By Ameco Research
pune, India, Fri, 07 May 2021 03:41:22 / Comserve Inc. / -- The global Caspase 3 market is segmented by company, region (country), by Type, and by...
Comserve · 05/07 07:42
RBC Capital Sticks to Its Buy Rating for Aptose Biosciences (APTO)
In a report issued on May 4, Gregory Renza from RBC Capital maintained a Buy rating on Aptose Biosciences (APTO), with a price target of $9.00. The
SmarterAnalyst · 05/07 01:49
Analysts Offer Insights on Healthcare Companies: Aptose Biosciences (APTO) and Arcutis Biotherapeutics (ARQT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aptose Biosciences (APTO) and Arcutis Biotherapeutics
SmarterAnalyst · 05/04 23:56
10-Q: APTOSE BIOSCIENCES INC.
(EDGAR Online via COMTEX) -- Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form...
Edgar Online - (EDG = 10Q, 10K) · 05/04 21:18
Aptose Biosciences Q1 EPS $(0.18) Misses $(0.14) Estimate
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 20 percent decrease over losses of $(0.15) per share from
Benzinga · 05/04 20:14
Aptose Biosciences EPS misses by $0.01
Aptose Biosciences (APTO): Q1 GAAP EPS of -$0.18 misses by $0.01.Total cash and cash equivalents and investments as of March 31, 2021 were $112.1 million. Based on current operations, Aptose
Seekingalpha · 05/04 20:02
Webull provides a variety of real-time APTO stock news. You can receive the latest news about Aptose through multiple platforms. This information may help you make smarter investment decisions.
About APTO
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.